1. Search Result
Search Result
Results for "

Humanized

" in MedChemExpress (MCE) Product Catalog:

434

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

574

Inhibitory Antibodies

203

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99264

    Humanized Anti-CD22 Recombinant Antibody

    ADC Antibody CD22 Cancer
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
    Inotuzumab
  • HY-P99302

    Humanized Anti-CD28 Recombinant Antibody

    CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
    Lulizumab
  • HY-P99308

    AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody

    CD20 Cancer
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
    Ocaratuzumab
  • HY-P9906A
    Bevacizumab (PBS)
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human VEGF, Humanized Antibody (PBS)

    VEGFR Cancer
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
    Bevacizumab (PBS)
  • HY-P9914

    Anti-Human C5, Humanized Antibody

    Complement System Cardiovascular Disease Cancer
    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
    Eculizumab
  • HY-P9906
    Bevacizumab
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human VEGF, Humanized Antibody

    VEGFR Cancer
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
    Bevacizumab
  • HY-P9907
    Trastuzumab
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody

    Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab
  • HY-P9917
    Tocilizumab
    20+ Cited Publications

    Anti-Human IL6R, Humanized Antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
    Tocilizumab
  • HY-P9910

    GA101; Anti-Human CD20 type II, Humanized Antibody

    CD20 Cancer
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
    Obinutuzumab
  • HY-P9802

    SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody

    SARS-CoV Infection
    Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
    Anti-Spike-RBD Single Domain mAb
  • HY-P9911
    Vedolizumab
    1 Publications Verification

    Anti-Human lymphocyte α4β7 integrin, Humanized Antibody

    Integrin Inflammation/Immunology Cancer
    Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
    Vedolizumab
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody (PBS)

    ADC Antibody EGFR Cancer
    Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P9997

    ANB030

    PD-1/PD-L1 Cancer
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
    Rosnilimab
  • HY-NP131

    Discoidin Domain Receptor Apoptosis Autophagy Cancer
    Recombinant Humanized Type III Collagen 30-40kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 30-40kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis .
    Recombinant Humanized Type III Collagen (30-40kDa)
  • HY-P99888

    EGFR Others
    Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
    Pimurutamab
  • HY-P99868

    MGD 011

    CD19 Others Cancer
    Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
    Duvortuxizumab
  • HY-P99118

    HLX 10

    PD-1/PD-L1 Cancer
    Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer .
    Serplulimab
  • HY-NP132

    Biochemical Assay Reagents Integrin Cancer
    Recombinant Humanized Type III Collagen (80-100kDa) is a type III collagen (80-100kDa). Recombinant humanized type III collagen (rhCOLIII) has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. rhCOLIII inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
    Recombinant Humanized Type III Collagen (80-100kDa)
  • HY-P9969

    EMD 72000

    EGFR Cancer
    Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .
    Matuzumab
  • HY-P99210

    CDP 6038; OKZ

    Interleukin Related Inflammation/Immunology
    Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA) .
    Olokizumab
  • HY-P99026

    TJ011133; TJC4

    CD47 Cancer
    Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
    Lemzoparlimab
  • HY-P99269

    BIBH 1; Anti-Human FAP Recombinant Antibody

    FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-P99773

    JS002

    PCSK9 Cardiovascular Disease Metabolic Disease
    Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
    Ongericimab
  • HY-P99854

    RC48-0

    EGFR ADC Antibody Cancer
    Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .
    Disitamab
  • HY-P99027

    LAG525; IMP701

    LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .
    Ieramilimab
  • HY-P99405

    PRX 002; RG 7935; RO 7046015

    α-synuclein Neurological Disease
    Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
    Prasinezumab
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
    Ruplizumab
  • HY-P99859

    LY3002813

    Amyloid-β Neurological Disease
    Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
    Donanemab
  • HY-P99021

    LY 2951742

    CGRP Receptor Neurological Disease
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
    Galcanezumab
  • HY-P99010

    FGFR Cancer
    Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research .
    Bemarituzumab
  • HY-P9960

    CD20 Inflammation/Immunology
    Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
    Ocrelizumab
  • HY-P9993

    LY-3462817

    PD-1/PD-L1 Cancer
    Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .
    Peresolimab
  • HY-P99015

    TNF Receptor Cancer
    Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
    Dacetuzumab
  • HY-P99372

    Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)

    ADC Antibody Cancer
    Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
    Lorvotuzumab
  • HY-P99310

    RG4934

    Interleukin Related Inflammation/Immunology
    Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
    Perakizumab
  • HY-P99442

    Hu1D10

    Apoptosis Inflammation/Immunology Cancer
    Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
    Apolizumab
  • HY-P99626

    LY 3015014

    PCSK9 Metabolic Disease
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
    Frovocimab
  • HY-P99106

    PD-1/PD-L1 Cancer
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
    Acrixolimab
  • HY-P9988

    BA301

    ADC Antibody TAM Receptor Cancer
    Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
    Mecbotamab
  • HY-P99019

    TEV-48125

    CGRP Receptor Neurological Disease
    Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
    Fremanezumab
  • HY-P99043

    Notch Cancer
    Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .
    Rovalpituzumab
  • HY-P99153

    MORAb-003

    Antibiotic Cancer
    Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
    Farletuzumab
  • HY-P99166

    PD-1/PD-L1 CTLA-4 Inflammation/Immunology Cancer
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
    Vudalimab
  • HY-P99507

    MCLA-128; PB4188; R040517

    EGFR Cancer
    Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
    Zenocutuzumab
  • HY-P99044
    Sabatolimab
    1 Publications Verification

    MBG453

    Tim3 Inflammation/Immunology Cancer
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
    Sabatolimab
  • HY-P99313

    Anti-Human IGHE Recombinant Antibody

    Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
    Quilizumab
  • HY-P99613

    MK-4280

    LAG-3 Cancer
    Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .
    Favezelimab
  • HY-P99962

    BGB-A425

    Mucin Cancer
    Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
    Surzebiclimab
  • HY-147407

    Others Cancer
    Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .
    Imbotolimod
  • HY-P99396

    BI 655130

    Interleukin Related Inflammation/Immunology
    Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
    Spesolimab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: